Click on a filter below to refine your search. Remove a filter to broaden your search.
Severely immunocompromised individuals had greater SARS-CoV-2 evolution and a higher risk for developing resistance against therapeutic mAbs.
The authors highlight that the volume of hospitalizations for COVID-19 was double that of the volume for flu.
The findings compared with placebo at 28-day and 43-day follow-up.
Care models are informed by five key principles, including multidisciplinary expertise and a patient-centered approach.
Supply disruptions increased for drugs with and without reports at the start of the COVID-19 pandemic.
In some individuals, there were many viral amino acid substitutions, indicating strong positive selection.
The panel is expected to focus on the safety of high-risk Americans, including people 65 and older and anyone with a weakened immune system.
Hypermobility also predicts greater fatigue levels.
Compared with those without COVID-19, similar deficits were seen for those in whom symptoms resolved in less than four or at least 12 weeks.
A second booster is appropriate as long as at least four months have passed since a person’s last COVID-19 shot.